Rather than develop vonoprazan in the U.S., Europe and Canada on its own, Takeda Pharmaceutical Co. Ltd. decided to spin the drug out into a new company, Phathom Pharmaceuticals Inc., with the help of venture capitalists at Frazier Healthcare Partners.